Fernández PG, Pérez HCL, Fernández RT

Language: Spanish
References: 19
Page: 1-3
PDF size: 818.49 Kb.

Text Extraction

No abstract.

REFERENCES

1. Suresh S, Rajvanshi PK, Noguchi CT. The Many Facets of Erythropoietin Physiologic and Metabolic Response. Front Physiol [Internet]. 2020 [Citado 08/08/2022];10:[Aprox. 2 p]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6984352/1.

2. Peng B, Kong G, Yang C, Ming Y. Erythropoietin and its derivatives: from tissue protection to immune regulation. Cell Death Dis [Internet]. 2020 [Citado 08/08/2022];11(2):1-12. Disponible en: https://www.nature.com/articles/s41419-020-2276-82.

3. Garzón F, Coímbra D, Parcerisas A, RodrÍguez Y, García JC, Soriano E, et al. NeuroEPO Preserves Neurons from Glutamate-Induced Excitotoxicity. J Alzheimer's Dis. 2018 Jan 1;65(4):1469-83.

4. Fernando G, Yamila R, César GJ, Ramón R. Neuroprotective Effects of neuroEPO Using an In Vitro Model of Stroke. Behavioral Sciences Multidisciplinary Digital Publishing Institute [Internet]. 2018 [Citado 08/08/2022];26:[Aprox. 2 p]. Disponible en: https://www.mdpi.com/2076-328X/8/2/26/htm4.

5. Maurice T, Mustafa MH, Desrumaux C, Keller E, Naert G, de la C García Barceló M, et al. Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aß25-35 non-transgenic mouse model of Alzheimer's disease. J Psychopharmacol. 2013;27(11):1044-57.

6. Cruz YR, Strehaiano M, Rodríguez Obaya T, Rodríguez JCG, Maurice T. An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APP Swe Transgenic Mouse Model of Alzheimer's Disease. J Alzheimer's Dis. 2017 Jan 1;55(1):231-48.

7. Sosa Teste I, Tamos YM, Cruz YR, Cernada AM, Rodríguez JC, Subirós N, et al. Dose effect evaluation and therapeutic window of the neuro-EPO nasal application for the treatment of the focal ischemia model in the Mongolian gerbil. Scientific World Journal [Internet]. 2012 [Citado 08/08/2022];2012:607498. Disponible en: http://europepmc.org/abstract/MED/227013647.

8. Rodríguez Cruz Y, Mengana Tamos Y, Muñoz Cernuda A, Subirós Martínez N, González Quevedo A, Sosa Testé I, et al. Treatment with nasal neuro-EPO improves the neurological, cognitive, and histological state in a gerbil model of focal ischemia. Scientific World Journal. 2010 Nov 16;10:2288-300.

9. Gao Y, Mengana Y, Cruz YR, Muñoz A, Testé IS, García JD, et al. Different expression patterns of ngb and epor in the cerebral cortex and hippocampus revealed distinctive therapeutic effects of intranasal delivery of neuro-epo for ischemic insults to the gerbil brain. J Histochem Cytochem [Internet]. 2011 Feb [Citado 08/08/2022];59(2):214-27. Disponible en: https://journals.sagepub.com/doi/full/10.1369/00221554103903239.

10. Santos Morales O, Díaz Machado A, Jiménez Rodríguez D, Pomares Iturralde Y, Festary Casanovas T, González Delgado CA, et al. Nasal administration of the neuroprotective candidate NeuroEPO to healthy volunteers: A randomized, parallel, open-label safety study. BMC Neurol [Internet]. 2017 Jul [Citado 08/08/2022];17(1):1-9. Disponible en: https://link.springer.com/articles/10.1186/s12883-017-0908-010.

11. García Llano M, Pedroso Ibáñez I, Morales Chacón L, Rodríguez Obaya T, Pérez Ruiz L, Sosa Testé I, et al. Short-term tolerance of nasally-administered NeuroEPO in patients with Parkinson disease. MEDICC Rev [Internet]. 2021 [Citado 08/08/2022];23(1):49-54. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=10455011.

12. Vega MLB, Shengnan L, León YR, Rodríguez AM, Fernández EC, Llano MG, et al. NeuroEPO improves cognition in Parkinson's disease. Preliminary report. MedRxiv [Internet]. New York: MedRxiv; 2022 [Citado 17/04/2022]. Disponible en: https://www.medrxiv.org/content/10.1101/2022.02.24.22271444v2

13. Pedroso I, García M, Casabona E, Morales L, Bringas ML, Pérez L, et al. Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson's Disease. Behav Sci [Internet]. 2018 May 21 [Citado 08/08/2022];8(5):51. Disponible en: https://www.mdpi.com/2076-328X/8/5/51/htm13.

14. Bringas Vega ML, Pedroso Ibáñez I, Razzaq FA, Zhang M, Morales Chacón L, Ren P, et al. The Effect of Neuroepo on Cognition in Parkinson's Disease Patients Is Mediated by Electroencephalogram Source Activity. Front Neurosci. 2022;1:952.

15. Rodríguez Labrada R, Ortega Sánchez R, Hernández Casaña P, Santos Morales O, Padrón Estupiñán M del C, Batista Núñez M, et al. Erythropoietin in Spinocerebellar Ataxia Type 2: Feasibility and Proof-of-Principle Issues from a Randomized Controlled Study. Mov Disord [Internet]. 2022 Jul [Citado 08/08/2022];37(7):1516-25. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/mds.2904515.

16. Pérez L, Sosa S, Bringas G, López D, Valenzuela C, Peñalver AI, et al. NeuroEPO in mild-to-moderate Alzheimer's disease. Alzheimer's Dement [Internet]. 2020 Dec [Citado 08/08/2022];16(S9):e036167. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/alz.03616716.

17. Suárez Borrás K, Fernández Peña G , Rodríguez Cruz Y, Puldón Seguí G. Intranasal administration of NeuroEPO does not affect the structure of respiratory mucosa in Wistar rats. Rev haban cienc méd [Internet]. 2022 [Citado 08/08/2022];21(4):[Aprox. 8 p.]. Disponible en: http://www.revhabanera.sld.cu/index.php/rhab/article/view/484917.

18. Fernández Romero T, Clapés Hernández S, Pérez Hernández CL, Barreto López JJ, Fernández Peña G, Fernández Romero T, et al. Efecto hipoglicemiante de la NeuroEPO en ratas con y sin diabetes mellitus. Rev Haban Cienc Méd [Internet]. 2022 [Citado 08/08/2022];21(1):[Aprox. 2p]. Disponible en: http://www.revhabanera.sld.cu/index.php/rhab/article/view/461718.

19. Fernández Romero T, Clapés Hernández S, Pérez CL, Núñez López N, Suárez Román G, Fernández G. Protective effect of NeuroEPO in the reproduction of diabetic rats. Rev haban cienc méd [Internet]. 2022 [Citado 08/08/2022];21(4):[Aprox. 6 p.]. Disponible en: http://www.revhabanera.sld.cu/index.php/rhab/article/view/479719.